CHARLOTTE, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited, (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced that members of the Prenetics management team will participate in two upcoming investor conferences.
iAccess Alpha Virtual Best Ideas Winter Conference 2024
Date: December 10-11, 2024
Location: Virtual
Presentation: December 10, 2024 at 10:00am ET
Webcast: https://www.webcaster4.com/Webcast/Page/3074/51539
Danny Yeung, Chief Executive Officer, will deliver a presentation on December 10, 2024, and will be joined by Stephen Lo, Chief Financial Officer, and David Vanderveen, President of Prenetics Americas, for one-on-one investor meetings to be held on December 11, 2024.
13th Annual ROTH Deer Valley Event
Date: December 11-13, 2024
Location: Park City, UT
David Vanderveen, President of Prenetics Americas, will be hosting one-on-one investor meetings throughout the conference.
Mr. Vanderveen has had a successful 30-year track record in beverage, nutrition, and technology, leading disruptive change at both Nirvana Water Sciences and XS Worldwide as prior CEO.
For more information or to schedule a meeting with management, please contact the Company’s investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Prenetics
Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for comprehensive genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer comprehensive DNA tests. Each of Prenetics’ units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science’. To learn more about Prenetics, please visit www.prenetics.com.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Angela Cheung
Investor Relations / Corporate Finance
Prenetics Global Limited
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.35 |
| Daily Change: | -0.30 -5.31 |
| Daily Volume: | 8,379 |
| Market Cap: | US$56.920M |
December 19, 2024 November 27, 2024 October 07, 2024 August 19, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
